AssetMark Inc’s Ionis Pharmaceuticals IONS Stock Holding History

AssetMark Inc’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$719K	Buy	9,574 +924	+11%	+$72.9K	﹤0.01%	1096
2025 Q4	$684K	Buy	8,650 +8,575	+11,433%	+$646K	﹤0.01%	1089
2025 Q3	$4.91K	Hold	75	–	–	﹤0.01%	2348
2025 Q2	$2.96K	Buy	75 +60	+400%	+$1.96K	﹤0.01%	2306
2025 Q1	$453	Sell	15 -17	-53%	-$557	﹤0.01%	2435
2024 Q4	$1.12K	Buy	+32	New	+$1.2K	﹤0.01%	2222
2024 Q2	–	Sell	-1	Closed	-$43	–	2175
2024 Q1	$43	Sell	1 -6	-86%	-$286	﹤0.01%	1848
2023 Q4	$354	Buy	+7	New	+$335	﹤0.01%	1705
2022 Q4	–	Sell	-250	Closed	-$11K	–	1621
2022 Q3	$11K	Buy	+250	New	+$10.5K	﹤0.01%	1213
2019 Q4	–	Sell	-25	Closed	-$2K	–	1428
2019 Q3	$2K	Hold	25	–	–	﹤0.01%	1169
2019 Q2	$2K	Hold	25	–	–	﹤0.01%	1166
2019 Q1	$2K	Hold	25	–	–	﹤0.01%	1171
2018 Q4	$1K	Hold	25	–	–	﹤0.01%	1319
2018 Q3	$1K	Hold	25	–	–	﹤0.01%	1344
2018 Q2	$1K	Hold	25	–	–	﹤0.01%	1343
2018 Q1	$1K	Sell	25 -46	-65%	-$2.34K	﹤0.01%	1338
2017 Q4	$4K	Buy	71 +66	+1,320%	+$3.62K	﹤0.01%	1292
2017 Q3	$0	Buy	+5	New	+$262	﹤0.01%	1538

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AssetMark Inc's IONS Position: Q1 2026 in Review

AssetMark Inc increased its Ionis Pharmaceuticals (IONS) stake by 11% in Q1 2026, buying an estimated $72.9K and bringing the position to 9,574 shares worth $719K. The position accounts for ﹤0.01% of the portfolio, ranked #1096.

AssetMark Inc first reported a position in IONS in Q3 2017 and has held it in 18 quarters since. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

AssetMark Inc held 9,574 shares of Ionis Pharmaceuticals worth $719K as of Q1 2026.
AssetMark Inc bought 924 Ionis Pharmaceuticals shares in Q1 2026, an estimated $72.9K.
Ionis Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #1096 holding.
AssetMark Inc first reported a position in Ionis Pharmaceuticals in Q3 2017 and has held it in 18 quarters since.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.